Elena Gambicorti

TL;DR: The clinical equivalence of this compound against ranibizumab is maintained even when the injections are administered at 8-week intervals, which indicates the potential to reduce the risk of monthly intravitreal injections and the burden of monthly monitoring.

TL;DR: The current literature and clinical trial data on the pathogenesis of PVR and its correlation with ocular trauma are reviewed and the biochemical/molecular events that will be fundamental for the development of novel treatment strategies are described.

TL;DR: The beneficial and adverse effects associated withinternal limiting membrane peeling in macular hole surgery are discussed, highlighting the internal limiting membrane's role in Macular hole etiology and pathogenesis and the anatomical and functional findings after its removal.

TL;DR: Of the interventions studied to date, PDT and micropulse laser treatment appear the most promising in treating central serous chorioretinopathy.

TL;DR: Since the use of these drugs is likely to become increasingly widespread and prolonged, it is desirable that the scientific community improves the pharmacovigilance program on all anti-VEGF drugs, expanding knowledge with studies that compares head to head all four compounds belonging to anti-veGF armamentarium.